Valye reports for unlimited access

Brenmiller Energy Ltd. develops and markets thermal energy storage systems using its patented bGen™ technology, which stores heat in crushed rocks at high temperatures for industrial and power applications. The TES systems provide flexible, dispatchable thermal energy to support electrification and decarbonization efforts, integrating renewable energy and reducing carbon emissions. The company offers modular, passive TES solutions with low maintenance and long lifetimes. Its business model includes direct equipment sales with after-sales services and Energy as a Service contracts where Brenmiller owns and operates TES systems at customer sites. In 2026, Brenmiller announced the BNRG360 integrated energy platform to bundle TES with solar photovoltaic and battery storage under long-term contracts. The company manufactures TES components in a facility in Dimona, Israel, with a current capacity of 1 GWh and potential expansion to 4 GWh. Brenmiller targets markets in the US, Europe, and Israel, with a growing pipeline of commercial projects and partnerships. The company has reported operating losses and negative cash flows since inception and is pursuing additional financing to support its commercialization efforts [S1][S2].

Hashdex Nasdaq CME Crypto Index ETF is a Delaware-registered exchange-traded fund listed on Nasdaq under the ticker NCIQ. The fund tracks the Nasdaq CME Crypto Settlement Price Index, having transitioned from the Nasdaq Crypto US Settlement Price Index effective January 20, 2026. The ETF operates under a Trust structure with a Sponsor and Trustee, and is classified as an emerging growth company. The fund's business model centers on providing investors exposure to a crypto asset index through an ETF vehicle. Operationally, the Trust has implemented infrastructure agreements to support staking activities and has enabled in-kind creation and redemption processes for authorized participants. Financial disclosures indicate a net loss for the fiscal year ending December 31, 2025, with limited other financial metrics disclosed.

Oak Valley Bancorp is a regional bank headquartered in Oakdale, California, serving primarily the Central California region including the Central Valley and foothill counties. The bank operates nineteen full-service branches and offers a comprehensive suite of banking products such as deposit accounts, commercial and consumer loans, and digital banking services. The company’s loan portfolio is predominantly real estate-related, reflecting its focus on the local real estate market. The bank competes with major national and regional banks as well as other financial institutions in its service area. Management emphasizes personalized service and local marketing to maintain competitive positioning. The company’s financial results for the fiscal year ended December 31, 2025, include net income of $23.9 million and basic EPS of $2.90, supported by asset growth and stable deposit funding.

Chenghe Acquisition III Co. is a blank check company incorporated in the Cayman Islands in June 2024. Its business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more target businesses. The company completed its Initial Public Offering in September 2025, issuing units at $10.00 each and raising gross proceeds of approximately $126.5 million, plus $4.08 million from private placement units sold to co-sponsors and underwriters. The proceeds are held in a Trust Account to be used for the initial business combination. The company has no operating revenues or business operations to date and generates income primarily from interest earned on Trust Account funds. It incurs costs related to being a public company and pursuing acquisition plans. The company’s shares and warrants trade on Nasdaq under the symbols CHEC and CHECW respectively after separation of units. The company’s ability to continue operations depends on completing an initial business combination within the prescribed timeframe, or it will be forced to liquidate.

UTG INC is a Delaware-incorporated insurance holding company headquartered in Stanford, Kentucky. Its main operating subsidiary, Universal Guaranty Life Insurance Company (UG), conducts individual life insurance business across 37 states. UTG itself has no significant operations and depends on dividends and fees from UG. The company maintains a philanthropic focus and is majority-owned by CEO Jesse T. Correll. UG's insurance products include fixed premium whole life policies and annuities, though new policy sales are currently limited. UTG also provides third-party administrative services, which contribute minimally to revenue. The company holds investments concentrated in oil and gas and related real estate royalties. UTG operates under extensive state insurance regulations and maintains adequate capitalization. The company has a stock repurchase program and reported $42.3 million in revenue and $17.1 million in net income for fiscal 2025.

Juniata Valley Financial Corp is a one-bank holding company with a long history dating back to 1867 through its bank charter. It operates primarily in central and northern Pennsylvania, serving local communities with retail and commercial banking services. The company’s offerings include personal and business checking and savings accounts, loans (including mortgages and commercial loans), debit cards, certificates of deposit, and wealth management and trust services. The bank’s deposit base is primarily local, and it competes with a range of financial institutions including community banks, regional and national banks, credit unions, and fintech providers. The company’s lending policies focus on sound underwriting and serving small to mid-sized businesses within its market area. Juniata Valley Financial maintains a stable deposit base and a diversified loan portfolio with detailed credit quality monitoring.

GENESCO INC is a multi-segment footwear and apparel company with key business units including Journeys Group, Schuh Group, Johnston & Murphy Group, and Genesco Brands Group. The company’s revenue streams derive from retail stores, e-commerce, wholesale, and branded product sales. Recent financial disclosures indicate modest growth in net sales and improvements in certain segments, notably Journeys Group, while others face challenges due to market conditions and tariff impacts. The company maintains liquidity through cash reserves and credit facilities, with ongoing capital investments focused on store renovations and expansions.

byNordic Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in Delaware, formed to effect an initial business combination. The company targets technology growth companies primarily in northern Europe, including Nordic and Scandinavian countries, the Baltic states, UK, Ireland, Germany, France, and Benelux countries. The management team has extensive experience in various technology sectors such as FinTech, digital infrastructure, software including AI, health technology, sustainability/climate technology, transportation technology, and industrial technology. The company completed its initial public offering in February 2022, raising gross proceeds of $150 million plus additional private placements, with funds held in a trust account. The company has extended its deadline to complete an initial business combination multiple times, currently until at least April 12, 2026. It has no operating business or revenue and will not engage in operations until the initial business combination is consummated. The company’s acquisition criteria focus on technology companies with enterprise valuations below $750 million, primarily between $150 million and $750 million, with differentiated products or services addressing unmet needs and growth opportunities. The company may use cash, debt, equity securities, or combinations thereof to effectuate the initial business combination. Officers and directors may have conflicts of interest due to ownership stakes and other fiduciary obligations, but independent opinions are sought for affiliated transactions. Public stockholders have redemption rights in connection with the initial business combination or if the combination is not completed by the deadline.

Galaxy Enterprises Inc. was incorporated in March 2021 and intends to provide real estate management and consulting services primarily in the Las Vegas, Nevada area. The company plans to offer property management services such as tenant screening, lease administration, rent collection, maintenance oversight, and financial reporting. Consulting services will include market analysis, property valuation, feasibility studies, strategic planning, and capital management advice. Revenue will be generated through monthly fees based on rental income percentages and hourly or negotiated consulting fees. The company has not yet commenced operations and currently has no employees other than its sole officer and director. Marketing efforts will leverage local real estate relationships and digital media platforms. The company operates in a highly competitive and fragmented market with established national and local competitors. It is subject to Nevada state licensing requirements for real estate brokers and property managers. Population growth and construction activity in the region are cited as factors increasing demand for its services [S1][S2].

Intrusion Inc., headquartered in Plano, Texas, is a cybersecurity firm offering proprietary threat intelligence and network security solutions. Its core product, INTRUSION Shield, is a Zero Trust SaaS platform that analyzes network traffic to block malicious connections, with variants for on-premise, cloud, and endpoint protection. The company also offers TraceCop, a comprehensive IP intelligence big data tool, and Savant, a network monitoring and forensic analysis solution used by U.S. government agencies. Intrusion's revenues are predominantly derived from U.S. government customers, accounting for over 94% of 2025 revenues. The company sells through direct sales and channel partners, including resellers and integrators. Intrusion reported $7.1 million in revenues and a net loss of $9.1 million for fiscal 2025, with liquidity ratios indicating moderate short-term financial stability. The company faces substantial doubt about its ability to continue as a going concern without additional financing. Competition is intense in the cybersecurity market, with principal competitors including Darktrace, Trellix, and Recorded Future, though TraceCop currently has few direct competitors due to its extensive historical data.

Spectral AI, Inc. is a medical technology company specializing in AI-enabled predictive diagnostics for burn wounds through its DeepView System. The system integrates proprietary multispectral imaging hardware and AI algorithms to classify wound tissue and predict healing outcomes at the initial patient presentation. The technology is designed to assist healthcare professionals in making timely and accurate treatment decisions, potentially reducing hospital stays and associated costs. The company’s business model includes a SaaS software licensing component and capital sales of imaging devices. Spectral AI has received substantial U.S. government funding, primarily from BARDA, supporting clinical validation, regulatory submissions, and product development. The company has achieved UKCA marking and is pursuing FDA De Novo clearance. It also develops additional products such as a handheld DeepView SnapShot M device and 3D wound measurement technology. The company employs a growing workforce and plans to expand commercial operations in the U.S. and UK markets, targeting burn centers, trauma centers, and emergency rooms. Key risks include regulatory uncertainties, supplier dependencies, capital requirements, and competition from other wound imaging technologies.

UiPath Inc is a technology company specializing in software infrastructure, providing an automation platform that enables enterprises to adopt agentic automation and AI-driven process improvements. The platform supports flexible deployment options including on-premises and cloud-based SaaS offerings. Revenue streams include software licenses, subscription services (maintenance, support, SaaS), and professional services such as deployment and training. The company emphasizes growth through expanding its customer base, increasing sales to existing customers, and leveraging channel partners and strategic alliances. UiPath invests heavily in research and development to maintain innovation leadership and competitive advantage in the automation and AI market. The company operates globally and faces macroeconomic and geopolitical risks that may impact demand and financial results. Seasonality affects sales cycles, with higher license agreements and renewals typically in the second half of the fiscal year. UiPath completed workforce restructurings in recent years to optimize operations and focus investments on AI and innovation.

Nexalin Technology, Inc. is a Houston-based medical device company focused on developing bioelectronic neurostimulation products to address mental health conditions. Its original Gen-1 device uses cranial electrotherapy stimulation at 4 milliamps and is FDA Class II for anxiety and insomnia treatment but is no longer actively marketed for new sales in the U.S. The company is developing next-generation devices, Gen-2 SYNC and Gen-3 HALO, which emit a proprietary 15 milliamp waveform designed for deeper brain stimulation without discomfort or side effects. These devices are undergoing FDA Q-submission and pre-submission processes, with clinical trials planned or underway in the U.S. and internationally. Nexalin is also building a virtual clinic platform to enable tele-psychiatry diagnosis and remote patient monitoring. The company holds regulatory approvals in China, Brazil, and Oman and has a joint venture for commercialization in China. Manufacturing is outsourced to U.S. contractors under FDA quality standards. Nexalin holds multiple patents protecting its technology and has a Military & Government Advisory Board to support deployment in federal agencies.

Social Commerce Partners Corporation is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on August 11, 2025. The company was formed to identify and complete a merger, share exchange, asset acquisition, or similar business combination with one or more target businesses, with an initial focus on the social commerce (direct selling) industry. The company completed its initial public offering on December 24, 2025, issuing 10 million units at $10.00 per unit, raising gross proceeds of $100 million, which were placed in a trust account invested in U.S. government treasury obligations or money market funds. The company has not yet selected any business combination target and has not engaged in substantive discussions with any potential targets. It has a 24-month window from the IPO closing to complete a business combination or else must redeem public shares. The company has no operating revenues and reported a net loss of $583,044 for the period from inception through December 31, 2025. It maintains a strong liquidity position with a current ratio of 7.23 as of December 31, 2025, and has contractual obligations including monthly payments for office space and administrative support. The company is classified as an emerging growth company and a smaller reporting company under SEC rules, with reduced disclosure requirements.

CoJax Oil & Gas Corp is an oil and gas company incorporated in Virginia, United States. It is classified as a smaller reporting company under SEC rules, which reduces its disclosure obligations. The company reported revenues under $1 million and a net loss exceeding $1 million for the fiscal year ending December 31, 2025. Liquidity metrics indicate significant short-term financial constraints, with current liabilities substantially exceeding current assets. The company filed a corporate presentation in mid-2025 outlining strategic developments, but detailed operational or product information is not publicly disclosed in SEC filings or news sources.

Range Capital Acquisition Corp II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on May 22, 2025. The company completed its IPO on October 6, 2025, raising gross proceeds of $230 million through the sale of 23 million units, each consisting of one Class A ordinary share and one-half of a redeemable warrant. Concurrently, it completed a private placement of 660,000 units, generating $6.6 million. The net proceeds from these offerings were placed in a Trust Account to be used primarily for completing a business combination with one or more target businesses. The company has not commenced operations or generated revenues and currently earns interest income on the Trust Account investments. The board of directors includes experienced individuals with backgrounds in investment management and SPACs. The company’s financial statements are prepared under US GAAP and audited by CBIZ CPAs P.C. The company maintains a strong liquidity position with cash and current assets exceeding current liabilities by a wide margin as of December 31, 2025.

Everpure, Inc. provides an integrated storage and data management platform known as the Everpure Platform, which virtualizes data across on-premises, hybrid, public cloud, and edge environments into a unified storage layer with consistent control and automation. The company addresses four major market trends: the shift to all-flash technology, growth of cloud-native applications, demand for storage-as-a-service, and increasing AI-driven data storage needs. Its six strategic growth pillars include expanding all-flash use cases, hybrid cloud data services, subscription service growth, integrated data management, dataset management across hybrid/multi-cloud, and AI portfolio expansion for GPU and HPC environments. Everpure's product portfolio includes FlashArray and FlashBlade systems powered by Purity software and DirectFlash hardware. The company serves over 14,500 customers globally, including 64% of Fortune 500 companies, and sells through direct and channel partners. It faces competition from established storage vendors and cloud providers and manages supply chain and operational risks through contract manufacturers and supplier relationships.

USBC, Inc. is focused on delivering a tokenized bank deposit product that leverages blockchain technology to provide retail customers worldwide access to U.S. dollar deposit accounts. The company is in the early stages of product delivery, currently conducting an internal pilot to test technical readiness. Strategic partnerships with Uphold HQ Inc. and Vast Bank, N.A. form the foundation of its tokenized deposit network, with exclusivity agreements in place for market making and exchange services. The company has not reported revenue recently and is operating at a net loss, supported by liquidity from cash and current assets.

Nasus Pharma Ltd, incorporated in Israel in 2019, is a clinical-stage specialty pharmaceutical company focused on developing innovative intranasal powder-based drug delivery products for emergency medical conditions such as anaphylaxis and opioid overdose. The company's proprietary Powder-Based Inhalation (PBI) technology aims to provide rapid and efficient drug absorption through the nasal cavity, potentially offering advantages over liquid nasal solutions. Nasus Pharma's lead product candidate, NS002, is an intranasal epinephrine powder designed to treat anaphylaxis, with clinical trials demonstrating faster and higher peak plasma epinephrine levels compared to intramuscular injections like EpiPen. The company has conducted multiple Phase 2 studies and plans to initiate a pivotal Phase 3 trial in late 2026. Nasus Pharma has paused development of NS001, an intranasal naloxone product, and is seeking partnerships for its further development. The company operates as a virtual entity with collaborations for manufacturing and device development, including agreements with Aptar. Nasus Pharma is publicly listed on the NYSE American under the ticker NSRX and has completed a $15 million private placement in early 2026. The company reported $1.235 billion in revenue and a net loss of $5.856 million for the fiscal year ended December 31, 2025, with liquidity ratios indicating a current ratio of 2.24 and a cash ratio of 0.57. Nasus Pharma faces competition from established intranasal emergency drug products and generics and is pursuing partnerships to accelerate development and commercialization of its pipeline.

Paysign, Inc. is a vertically integrated payment processor and prepaid card program manager that provides prepaid card products and processing services to corporate, consumer, and government entities. The company’s payment solutions are designed to increase customer loyalty, improve patient adherence, reduce administrative costs, and streamline operations. Paysign’s product suite includes corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, pharmaceutical payment assistance, demand deposit accounts, and software solutions for blood and plasma collection organizations. The company’s cards are issued through bank partners and accepted on major payment networks. Paysign also offers a cloud-based technology platform for blood and plasma collection organizations under the Apherion™ brand. The company operates a bilingual, 24/7 in-house customer service center and employs a scalable, secure technology platform with cloud hosting and data analytics capabilities. Paysign competes in a fragmented market with a focus on direct marketing and strategic partnerships. As of December 31, 2025, Paysign managed approximately 670 card programs with about 8.4 million cardholders.

QT Imaging Holdings, Inc. develops and commercializes innovative breast imaging systems based on low-energy transmitted sound technology. Founded in 2012 and headquartered in Novato, California, the company aims to improve breast cancer screening and diagnostics by providing high-resolution, 3D volumetric images without ionizing radiation or breast compression. Its flagship product, the Breast Acoustic CT scanner, has received FDA 510(k) clearances, including enhancements for improved imaging coverage. The company is transitioning from a hardware manufacturer to a precision imaging platform by integrating cloud-based AI and machine learning capabilities through a SaaS model. QT Imaging targets intermediate and high-risk women, especially those with dense breast tissue, addressing limitations of current imaging modalities. Manufacturing is conducted internally and via contract manufacturing partnerships. The company has established strategic distribution agreements in the Gulf Cooperation Council region and plans further international expansion. Financially, QT Imaging reported a net loss of $21.1 million for 2025, with no revenue reported for 2023, and maintains liquidity with $10.4 million in cash and equivalents as of year-end 2025.

Enlivex Ltd. is a clinical-stage biotechnology company specializing in quality longevity therapies through macrophage reprogramming immunotherapy. Its lead product candidate, Allocetra™, is based on licensed apoptotic cell technology and is being developed primarily for inflammatory diseases such as osteoarthritis. The company holds a broad portfolio of patents and pending applications worldwide to protect its technology. Manufacturing of Allocetra™ occurs at a cGMP-certified facility in Ness Ziona, Israel, producing a frozen formulation to support clinical trials. Enlivex outsources clinical trial activities to CROs and currently does not have internal sales or marketing capabilities, intending to seek partnerships for commercialization. Financially, the company reported net income and strong liquidity as of the end of 2025, supported by recent capital raises. The company operates through subsidiaries in Israel, the US, and Poland.

Chewy, Inc. operates as a preeminent online retailer of pet products, supplies, and prescriptions, serving customers primarily in the U.S. and Canada through its websites and mobile applications. The company offers approximately 190,000 products from about 4,000 trusted brands, including its own private labels. Chewy emphasizes customer service, competitive pricing, and personalized engagement, supported by a scalable technology platform and a network of fulfillment centers enabling rapid delivery. The company has expanded into pet healthcare services, including telehealth, pharmacy, and veterinary clinics, and has launched an e-commerce platform for veterinarians. Chewy also operates a subscription-based Autoship program to enhance customer retention. The pet industry is large and growing, with increasing online sales and pet humanization trends supporting demand. Chewy faces strong competition across multiple retail and veterinary channels, competing on price, selection, delivery, and service.

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, including obesity. The company leverages its proprietary Compass platform, which integrates human genetics and variant functionalization to identify and validate novel drug targets. Maze’s pipeline includes two wholly-owned clinical programs: MZE829, an oral inhibitor of APOL1 for APOL1-mediated kidney disease, currently in Phase 2 clinical trials; and MZE782, poised for Phase 2 development targeting PKU and CKD. Additionally, Maze has a partnered program licensed to Shionogi for Pompe disease in Phase 2. The company completed its IPO in February 2025, raising net proceeds of approximately $127.8 million. As of December 31, 2025, Maze reported strong liquidity with cash and short-term investments totaling over $341 million, but also a net loss of $131.1 million for the fiscal year. The company faces competition from established and novel therapies in the kidney disease space and emphasizes intellectual property protection as a key component of its strategy. Recent news highlights include positive Phase 2 topline data for MZE829 and multiple analyst coverage initiations with buy and outperform recommendations.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for retinal diseases, primarily focusing on inherited and age-related degenerative retinal conditions such as retinitis pigmentosa (RP). Its lead product, KIO-301, is a novel photoswitch small molecule designed to restore vision by modulating ion channels in retinal neurons. KIO-301 completed Phase 1b trials with positive safety and efficacy signals and is currently in a Phase 2 trial (ABACUS-2) enrolling patients with ultra-low vision or no light perception. The company has partnered with Théa Open Innovation for global development and commercialization rights outside certain Asian countries and has an option agreement with Senju for Asian territories. Kiora is also developing KIO-104, a potent DHODH inhibitor targeting retinal inflammatory diseases such as diabetic macular edema and posterior non-infectious uveitis, with Phase 2 trials underway. Additionally, KIO-101, a topical formulation of the same active compound as KIO-104, targets ocular manifestations of autoimmune diseases. The company does not currently generate product revenue and finances operations through equity, collaborations, and licensing. As of December 31, 2025, Kiora maintains strong liquidity with cash, short-term investments, and a high current ratio, supporting ongoing clinical development and strategic initiatives.

Concord Acquisition Corp II is a Delaware-incorporated special purpose acquisition company (SPAC) trading on the OTCQX market under the ticker CNDA. The company holds cash and short-term investments and is focused on identifying and completing a business combination. As of the fiscal year ended December 31, 2025, the company reported net income but no revenue or operational segment data. The company extended its deadline to consummate a business combination to December 31, 2025. It recently changed its independent auditor from Marcum LLP to CBIZ CPAs P.C. with no reported disagreements.

Aldel Financial II Inc. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2024. The company’s business purpose is to merge, acquire, or combine with one or more businesses, with a focus on the financial services industry but without limitation to any sector or geography. The company completed its initial public offering (IPO) in October 2024, issuing 23 million units at $10 per unit, raising gross proceeds of $230 million, alongside private placements totaling approximately $7.175 million. The proceeds were placed primarily in a trust account invested in short-term U.S. Treasury obligations, with a small portion retained for working capital and expenses. As of the end of 2025, Aldel Financial II had not commenced operations or generated operating revenues, reflecting its status as an early-stage SPAC. The company’s shares and warrants trade on Nasdaq under the symbols ALDF, ALDF.U, and ALDF.W. The company’s financial statements show a strong liquidity position with a current ratio of 2.7 and cash ratio of 2.15 as of December 31, 2025. Net income reported for the year ended December 31, 2025, primarily reflects investment income on the trust account rather than operating activities. The company is subject to risks typical of SPACs, including the ability to identify and complete a business combination and potential conflicts of interest with its Sponsor and management.

SecureTech Innovations, Inc. is a technology company specializing in AI-driven manufacturing systems, blockchain infrastructure, and automotive safety technologies. It operates three primary segments: AI UltraProd, which delivers industrial 3D printing robotics and related services; Piranha Blockchain, focused on blockchain and cybersecurity platforms; and Terra Nova Technologies, which develops automotive safety products under the Top Kontrol brand. AI UltraProd's products serve construction, renewable energy, logistics, and warehousing sectors, offering integrated hardware, software, and technical support. Piranha Blockchain develops secure data centers and digital asset management solutions. Terra Nova Technologies is preparing for a spin-off of its automotive safety business. The company is expanding operations geographically and pursuing a NASDAQ uplisting.

Range Capital Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2024. Its business purpose is to identify and complete a business combination with one or more target companies, without limitation to industry or geography. The company has not yet identified or engaged with any target business and has not generated operating revenues. It completed an initial public offering in December 2024, raising gross proceeds of $100 million plus additional private placements and over-allotment proceeds, with approximately $115.6 million held in a trust account invested in short-term U.S. government securities. The management team is led by Tim Rotolo, who has experience in investment and operational roles across various sectors. The company plans to pursue a generalist acquisition strategy focusing on companies with scarce assets, pure play business models, and strong management, primarily in North America with enterprise values above $500 million. The company may use cash, debt, or equity to fund the business combination and may seek additional financing. As of December 31, 2025, the company reported no cash and cash equivalents outside the trust account, current assets of $417,317, and net income of $4,035,451 for the fiscal year. Basic and diluted EPS were -$0.01 for the third quarter of 2024. The company is an emerging growth and smaller reporting company, affecting disclosure requirements.

Braze, Inc. provides a cloud-based customer engagement platform that enables brands to deliver personalized messaging across multiple channels. Founded in 2011, the company has experienced rapid revenue growth in recent years but continues to operate at a net loss. Braze's platform depends on third-party cloud infrastructure and mobile operating systems, and the company invests heavily in technology development, sales and marketing, and international expansion. The business model relies on subscription renewals and expansion within existing customers, as well as attracting new customers. Braze faces a competitive market with established and emerging players and is subject to various operational and financial risks.

Rentokil Initial plc is a UK-incorporated public limited company specializing in pest control and hygiene and wellbeing services globally. The company operates over 2,000 facilities across 90 countries and has a significant presence in North America following its acquisition of Terminix Global Holdings in 2022. Its business model centers on protecting people from pest-borne diseases and poor hygiene risks, enhancing customer brand reputation, and pursuing sustainability in operations. The company invests in innovation with dedicated R&D centers, including the Rentokil Terminix North America Innovation Centre. Financially, Rentokil reported net income of $470 million USD for 2025 and maintains liquidity with a current ratio above 1.0. The executive leadership team oversees strategy execution and risk management. Recent market commentary and analyst reports highlight Rentokil as a key player in the business services sector with mixed analyst recommendations reflecting valuation debates [S1][N3][N5][N6].

Bright Mountain Media, Inc. is a digital advertising technology and media company that distributes content and advertising across various platforms. The company has experienced recurring losses and significant accumulated deficits, raising substantial doubt about its ability to continue as a going concern. It relies heavily on borrowings under a secured credit facility with Centre Lane Partners, which holds a significant ownership stake and controls the company's debt. The company’s revenues are concentrated among a few customers and are subject to seasonal fluctuations typical of the advertising industry. It faces risks from intense competition, rapid technological changes including AI, and challenges in maintaining effective internal controls. The company is actively exploring strategic alternatives including debt restructuring and capital raising to improve its financial position [S1].

Absci Corp is a biotechnology company that develops an Integrated Drug Creation platform combining AI, automation, and biologic drug discovery technologies. The platform is designed to accelerate the drug creation process by enabling efficient preclinical and clinical development activities. The company began commercial operations in 2018 and primarily generates revenue through partnerships involving drug creation activities rather than commercial product sales. Absci’s business model relies on advancing internally developed programs and partnering with third parties to generate milestone payments and royalties from product candidates discovered using its platform. As of late 2025, no partner has licensed intellectual property for clinical or commercial use, reflecting the early stage of the company’s commercial adoption. The company maintains operations internationally, including offices in Switzerland and Serbia, and faces typical risks associated with biologic drug development, regulatory approval, and supply chain dependencies.

BTC Development Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in April 2023. Its business objective is to identify and complete an initial business combination with one or more target companies, with a focus on businesses that can leverage bitcoin technology and treasury strategies. The company has not commenced operations beyond organizational activities, IPO, and target search. It completed its IPO on October 1, 2025, raising gross proceeds of $253 million, which are held in a trust account invested in U.S. government securities and money market funds. The company has a single reportable segment and evaluates performance at the corporate level. Management has prior experience with multiple blank check companies and business combinations in fintech and bitcoin-related sectors. The company incurs costs related to being a public company and due diligence activities. It has no revenues or operating history and does not expect revenues until after a business combination.

Willamette Valley Vineyards, Inc. produces and markets premium wines primarily from Oregon varietals including Pinot Noir, Pinot Gris, Chardonnay, Riesling, and Sparkling wines. The company operates vineyards, wineries, and tasting rooms, selling through direct-to-consumer channels (tasting rooms, wine clubs, internet sales) and distributors both in-state and out-of-state. Direct-to-consumer sales accounted for approximately 54.4% of revenue in 2025, with distributor sales making up the remainder. The company emphasizes growth in direct sales through hospitality centers and wine club memberships, though memberships decreased slightly in 2025. The company sold about 173,014 cases of wine in 2025, a 7.2% decline from 2024, reflecting lower sales across channels. The company invests in vineyard development and production capacity, operating two wineries with combined capacity exceeding current production. It faces competition from larger California wineries marketing Oregon-branded wines. The company has a revolving credit facility and maintains liquidity with a current ratio of 2.7 as of year-end 2025.

Andretti Acquisition Corp. II is a Special Purpose Acquisition Company (SPAC) incorporated in May 2024 in the Cayman Islands. Its sole purpose is to identify and complete a Business Combination with one or more target companies. The company completed its IPO in September 2024, issuing 23 million Public Units and raising gross proceeds of $230 million, plus a private placement of 760,000 units. The proceeds are held in a trust account to be used for the Business Combination. The company has not generated operating revenues and does not expect to do so until after completing a Business Combination. The management team includes experienced executives and advisors with prior SPAC experience. The company’s acquisition strategy focuses on well-established companies with competitive advantages, strong management, attractive financial profiles, and growth potential. It has until September 9, 2026, to complete its initial Business Combination or face liquidation and distribution of trust account funds to shareholders. The company terminated a prior Business Combination agreement with StoreDot Ltd. in February 2026 and is seeking alternative transactions. Financially, as of December 31, 2025, the company holds cash and equivalents of approximately $876,000, current assets of $162,000, and current liabilities of $191,000, with a current ratio below 1.0 but a high cash ratio. Net income for the fiscal year ending December 31, 2025, was $8.35 million, with diluted EPS of $0.08 for Q3 2025. The company’s shares and warrants trade on Nasdaq under symbols POLE, POLEU, and POLEW.